203 related articles for article (PubMed ID: 7478476)
21. Second solid malignancies after combined modality therapy for Hodgkin's disease.
Doria R; Holford T; Farber LR; Prosnitz LR; Cooper DL
J Clin Oncol; 1995 Aug; 13(8):2016-22. PubMed ID: 7636543
[TBL] [Abstract][Full Text] [Related]
22. Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study.
Cimino G; Papa G; Tura S; Mazza P; Rossi Ferrini PL; Bosi A; Amadori S; Lo Coco F; D'Arcangelo E; Giannarelli D
J Clin Oncol; 1991 Mar; 9(3):432-7. PubMed ID: 1999712
[TBL] [Abstract][Full Text] [Related]
23. Second malignant lesions after therapy for Hodgkin's disease.
Schomberg PJ; Evans RG; Banks PM; White WL; O'Connell MJ; Earle JD
Mayo Clin Proc; 1984 Jul; 59(7):493-7. PubMed ID: 6588280
[TBL] [Abstract][Full Text] [Related]
24. Incidence of second solid cancer in patients after treatment of Hodgkin's disease.
Glanzmann C; Veraguth A; Lütolf UM
Strahlenther Onkol; 1994 Mar; 170(3):140-6. PubMed ID: 8160093
[TBL] [Abstract][Full Text] [Related]
25. [Malignant lymphoma associated with HIV infection].
Mitrou PS; Serke M; Pohl C; Becker K; Schrappe-Bächer M; Knauf W; Westerhausen M; Clemens MR; Helm EB; Fischer T
Dtsch Med Wochenschr; 1991 Aug; 116(33):1217-23. PubMed ID: 1874122
[TBL] [Abstract][Full Text] [Related]
26. Hodgkin's disease: complications of therapy and excess mortality.
Hoppe RT
Ann Oncol; 1997; 8 Suppl 1():115-8. PubMed ID: 9187444
[TBL] [Abstract][Full Text] [Related]
27. Second malignant tumors after elective end of therapy for a first cancer in childhood: a multicenter study in Italy.
Rosso P; Terracini B; Fears TR; Jankovic M; Fossati Bellani F; Arrighini A; Carli M; Cordero di Montezemolo L; Garrè ML; Guazzelli C
Int J Cancer; 1994 Nov; 59(4):451-6. PubMed ID: 7960210
[TBL] [Abstract][Full Text] [Related]
28. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation.
Del Cañizo Mf; Amigo Mf; Hernández JM; Sanz G; Núñez R; Carreras E; Alegre A; Cuesta B; Mataix R
Haematologica; 2000 Apr; 85(4):403-9. PubMed ID: 10756367
[TBL] [Abstract][Full Text] [Related]
29. [Secondary non-Hodgkin's lymphomas].
Cappelaere P
Bull Cancer; 1998 Mar; 85(3):217-31. PubMed ID: 9752310
[TBL] [Abstract][Full Text] [Related]
30. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.
Schaapveld M; Aleman BM; van Eggermond AM; Janus CP; Krol AD; van der Maazen RW; Roesink J; Raemaekers JM; de Boer JP; Zijlstra JM; van Imhoff GW; Petersen EJ; Poortmans PM; Beijert M; Lybeert ML; Mulder I; Visser O; Louwman MW; Krul IM; Lugtenburg PJ; van Leeuwen FE
N Engl J Med; 2015 Dec; 373(26):2499-511. PubMed ID: 26699166
[TBL] [Abstract][Full Text] [Related]
31. [Malignant lymphoma of the neck, nose and pharyngeal region].
Cerny T
Schweiz Rundsch Med Prax; 1993 Dec; 82(50):1447-51. PubMed ID: 8290837
[TBL] [Abstract][Full Text] [Related]
32. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.
Salloum E; Doria R; Schubert W; Zelterman D; Holford T; Roberts KB; Farber LR; Kiehl RK; Cardinale J; Cooper DL
J Clin Oncol; 1996 Sep; 14(9):2435-43. PubMed ID: 8823321
[TBL] [Abstract][Full Text] [Related]
33. Hodgkin's disease and acute leukemia. Is it a true association?
Avilés A; Díaz-Maqueo JC; Ayala JR; Cortés HD; García EL
Arch Med Res; 1992; 23(1):65-8. PubMed ID: 1308794
[TBL] [Abstract][Full Text] [Related]
34. Current role of radiotherapy in Hodgkin's and non-Hodgkin's lymphoma.
Shulman LN; Mauch PM
Curr Opin Oncol; 1995 Sep; 7(5):421-5. PubMed ID: 8541386
[TBL] [Abstract][Full Text] [Related]
35. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
36. Persistent abnormalities in red cell parameters following treatment of lymphoma.
Meytes D; Leshno D; Berkowicz M; Modan M; Ramot B
Leuk Lymphoma; 1994 Oct; 15(3-4):341-5. PubMed ID: 7866284
[TBL] [Abstract][Full Text] [Related]
37. Hodgkin's disease: summary of twenty years' experience.
Mazza P; Bocchia M; Zinzani PL; Fiacchini M; Gherlinzoni F; Bandini G; Bendandi M; Frezza GP; Neri S; Barbieri E
Haematologica; 1992; 77(6):487-93. PubMed ID: 1283856
[TBL] [Abstract][Full Text] [Related]
38. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
Pedersen-Bjergaard J; Ersbøll J; Sørensen HM; Keiding N; Larsen SO; Philip P; Larsen MS; Schultz H; Nissen NI
Ann Intern Med; 1985 Aug; 103(2):195-200. PubMed ID: 4014901
[TBL] [Abstract][Full Text] [Related]
39. Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.
Friedberg JW
Haematologica; 2008 Mar; 93(3):336-8. PubMed ID: 18310538
[No Abstract] [Full Text] [Related]
40. Treatment results of tonsillar lymphoma: a 10-year experience.
Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
